Synairgen used Niche's expertise in the writing of manuscripts to quickly and efficiently develop high-quality documents for submission to relevant journals. Niche's high standards of manuscript preparation and ability to adapt to different journal requirements ensured successful publication. Services included:
"We thank Niche for the enormous contribution they made to moving the Synairgen interferon beta treatment for COVID-19 forwards. We recognise and hugely appreciate the tenacity, adaptiveness dexterity and sheer hard work."
Niche was approached by Synairgen for support in their interferon beta treatment (SNG001) for COVID-19 and COPD during the pandemic. Niche provided support in the development of manuscripts and regulatory documentation for the Phase II data in COVID-19 and COPD, the revolutionary approach to dosing in the home environment and the initiation of a Phase III trial. The Niche team’s expertise in quick and efficient manuscript writing helped Synairgen stay at the forefront of the wave of treating COVID-19.
Niche's work helped Synairgen get recognised by investors worldwide, which at the time, led to the largest fund raising drive ever experienced by the company. This allowed Synairgen the best opportunity to continue testing their product in further clinical trials. Based on the successful Phase II trial with SNG001 for which Niche contributed massively, Synairgen has since been able to initiate a Phase III trial in 17 countries.
Niche built and coordinated the full communications strategy for this 20-institution European initiative, turning.
read morePutting patients first, Niche supported ViiV Healthcare's global HIV outreach programmes with medical writing,.
read moreFrom Phase 2 through to the global Phase 3 HEAL-MI trial, Niche has been Recardio's trusted writing and regulatory.
read moreWhen stalled regulatory documentation threatened to derail their neurological programme, Cleothena turned to Niche —.
read moreOver a decade and 20+ guidelines later, Niche remains the BSH's trusted partner for raising haematology care standards.
read moreNiche provided Astex with expert regulatory writing across their oncology pipeline, delivering clinical protocols, study.
read moreNiche supported Nabriva's antibiotic lefamulin from early clinical protocols all the way to FDA, EMA and Health Canada.
read moreNiche delivered rigorous QC and medical writing support across Adaptimmune's full suite of regulatory documents, keeping.
read moreFor over a decade, Assign DMB relied on Niche as their embedded writing partner, seamlessly converting statistical.
read moreA trusted writing partner to this Belfast-based early-phase CRO for over a decade, Niche turned BioKinetic Europe's.
read moreNiche served as the English-language regulatory writing backbone for this Nordic consultancy, producing IBs, IMPDs and.
read moreGet our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
